Zydus Lifesciences Limited has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its oncology injectable manufacturing facility at SEZ-1, Ahmedabad, marking a key regulatory milestone for the company.
The inspection, conducted between November 4 and November 13, 2025, was related to the company’s new isolator-based injectable manufacturing line, and the receipt of EIR indicates a successful closure of the regulatory review process.
The development is significant as the oncology injectables segment is a high-value, complex generics market, and regulatory clearances from the USFDA are critical for supplying products to the US and other regulated markets.
The receipt of EIR strengthens Zydus’ position in the sterile injectables and oncology portfolio, an area where global demand continues to rise due to increasing cancer incidence and growing adoption of advanced therapies.
Zydus Lifesciences shares were trading at ₹936.85, up marginally by 0.09% during the session.